Efficacy of Pemetrexed Combined with Oxaliplatin or Gemcitabine in Advanced Non-Small Cell Lung Cancer

Objective:To evaluate the short-term efficacy and toxicities of pemetrexed combined with oxaliplatin or gemcitabine as second-line treatment for advanced non-small cell lung cancer.Methods:With the method of lottery,30 patients with advanced non-small cell lung cancer were divided into two groups: the study group,pemetrexed combined with oxaliplatin(n=15);and the control group,pemetrexed combined with gemcitabine(n=15).Pemetrexed(500 mg/m2,iv drip,d1) combined with oxaliplatin(130 mg/m2,iv drip,d1) were given every 3-4 weeks as a cycle for 2-4 cycles in the study group;pemetrexed(500 mg/m2,iv drip,d1) combined with gemcitabine(1250 mg/m2,iv drip,d1 an d8) were given every 3-4 weeks as a cycle for 2-4 cycles in the control group.Results:(1) The short term effects: the effective rate was 33.3%(5/15) in the study group and 26.6%(4/15) in the control group(P0.05).The effective rate was 38%(8/21) in adenocarcinoma patients and 22.2%(2/9) in squamous cell carcinoma patients(P0.05);(2) The study of Karnofsky performance status(KPS): the effective rate of the study group was 73.3%(11/15) and 53.3%(8/15) in the control group(P0.05);(3)The study of side effects: the hematologic toxicity in the study group was significantly lower than that in the control group(P0.05).The other side effects in the two groups had no statistical difference(P0.05).Conclusions: The combination regiment of pemetrexed and oxaliplatin as second-line treatment for advanced non-small cell lung cancer has good efficacy.